Derivation of the clinical grade human embryonic stem cell line RCe021-A (RC-17)

详细信息    查看全文

• 作者：P.A. De Sousa^a ; ^b ; ^c ; ^{paul.desousa@ed.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; ^{paul.desousa@roslincells.com" class="auth_mail" title="E-mail the corresponding author} ; ; B.J. Tye^a ; K. Bruce^a ; P. Dand^a ; G. Russell^a ; D.M. Collins^a ; A. Greenshields^a ; K. McDonald^a ; H. Bradburn^a ; D. Allan^a ; A. Laurie^a ; T. Kunath^c ; M.A. Canham^c ; J.M. Downie^a ; M. Bateman^a ; A. Courtney^a
• 刊名：Stem Cell Research
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：17
• 期：1
• 页码：1-5
• 全文大小：779 K

文摘

The human embryonic stem cell line RCe021-A (RC-17) was derived under quality assured compliance with UK regulation, European Union Directives and International guidance for tissue procurement, processing and storage according to Good Manufacturing Practice (GMP) standards. The cell line was derived from a day 3 embryo voluntarily donated as unsuitable or surplus to fertility requirements following informed consent. RCe021-A (RC-17) shows normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a normal 46XX female karyotype and microsatellite PCR identity, HLA and blood group typing data are available.